Covid vaccine: India's Covaxin gets emergency use approval for kids aged 2-18
In August, the government had granted ZyCov-D the same
An Indian expert committee on Covid-19 has given emergency use approval to Covaxin for children in the 2-18 group, it was announced on Tuesday.
“After detailed deliberation the subject expert committee recommended for grant of market authorisation of the vaccine for the age group of two to 18 for restricted use in emergency situation,” said a statement by the official panel. The vaccines will be administered in two doses with a gap of 20 days in between.
Bharat Biotech, the Hyderabad-based company, had last month completed phase two and three trials of Covaxin on children below 18. The expert committee has imposed certain conditions for the emergency use authorisation. The company will have to provide safety data after every 15 days during the first two months, and monthly thereafter.
Earlier in August, the government had granted emergency use approval for ZyCov-D, a vaccine made by Indian pharma major Zydus Cadila for children in the same age group.
The World Health Organization (WHO), however, has still to grant emergency use authorisation to Covaxin. Bharat Biotech had submitted the requisite documents to WHO in July and is awaiting its approval.
Seha shows appreciation for Abu Dhabi's frontline heroes. READ MORE
Threat of Covid infection still exists and people must do all they... READ MORE
The city is considering a number of 'exciting options' to replace it. READ MORE
The initiative will be held on October 17 and 18 READ MORE
Winds to cause blowing dust at times READ MORE
Operating capacity amended READ MORE
Motorists who pay e-ticket fines within 30 days of issuance will... READ MORE
Gopinath to return to Harvard University's economics department READ MORE